35,000 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Samsara BioCapital LLC

Samsara BioCapital LLC purchased a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 35,000 shares of the company's stock, valued at approximately $891,000. Samsara BioCapital LLC owned about 0.07% of Bicara Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of BCAX. First Turn Management LLC purchased a new position in shares of Bicara Therapeutics during the third quarter worth approximately $14,324,000. The Manufacturers Life Insurance Company bought a new stake in Bicara Therapeutics in the third quarter worth $582,000. FMR LLC purchased a new stake in Bicara Therapeutics during the third quarter valued at about $57,913,000. Walleye Capital LLC purchased a new position in shares of Bicara Therapeutics in the third quarter worth about $809,000. Finally, Vestal Point Capital LP purchased a new stake in Bicara Therapeutics during the 3rd quarter valued at about $10,825,000.

Analyst Ratings Changes

A number of equities research analysts recently commented on BCAX shares. Stifel Nicolaus started coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set a "buy" rating and a $47.00 price target for the company. Morgan Stanley began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an "overweight" rating and a $35.00 target price for the company. Cantor Fitzgerald initiated coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued an "overweight" rating for the company. Rodman & Renshaw began coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a "buy" rating and a $48.00 target price for the company. Finally, RODMAN&RENSHAW raised Bicara Therapeutics to a "strong-buy" rating in a research note on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $43.33.

Insider Activity

In related news, major shareholder James E. Flynn purchased 70,000 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the transaction, the insider now directly owns 897,587 shares in the company, valued at $16,156,566. This represents a 8.46 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the business's stock in a transaction that occurred on Monday, September 16th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the acquisition, the director now directly owns 4,303,418 shares in the company, valued at $77,461,524. The trade was a 74.20 % increase in their position. The disclosure for this purchase can be found here.

Bicara Therapeutics Trading Down 2.8 %

Bicara Therapeutics stock traded down $0.56 during midday trading on Thursday, hitting $19.39. The stock had a trading volume of 132,443 shares, compared to its average volume of 352,316. Bicara Therapeutics Inc. has a 52-week low of $17.41 and a 52-week high of $28.09. The stock has a fifty day moving average of $21.94.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, analysts predict that Bicara Therapeutics Inc. will post -2.89 EPS for the current year.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.